Teleflex (TFX) to Release Quarterly Earnings on Thursday

Teleflex (NYSE:TFX) is projected to announce its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of $3.38 per share and revenue of $892.7850 million for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:00 AM ET.

Teleflex Price Performance

Shares of NYSE TFX opened at $124.53 on Wednesday. Teleflex has a twelve month low of $108.90 and a twelve month high of $209.67. The firm has a fifty day simple moving average of $126.45 and a 200 day simple moving average of $123.36. The company has a market capitalization of $5.50 billion, a PE ratio of 29.30, a P/E/G ratio of 1.79 and a beta of 1.05. The company has a quick ratio of 1.44, a current ratio of 2.41 and a debt-to-equity ratio of 0.42.

Institutional Investors Weigh In On Teleflex

A number of large investors have recently added to or reduced their stakes in TFX. Cerity Partners LLC boosted its position in Teleflex by 159.6% in the 2nd quarter. Cerity Partners LLC now owns 23,126 shares of the medical technology company’s stock valued at $2,737,000 after buying an additional 14,219 shares during the period. Jump Financial LLC purchased a new position in Teleflex in the second quarter worth $987,000. Amundi grew its holdings in Teleflex by 94,478.1% in the second quarter. Amundi now owns 30,265 shares of the medical technology company’s stock worth $3,680,000 after purchasing an additional 30,233 shares during the last quarter. American Century Companies Inc. increased its stake in Teleflex by 32.7% during the 2nd quarter. American Century Companies Inc. now owns 13,640 shares of the medical technology company’s stock valued at $1,614,000 after purchasing an additional 3,360 shares in the last quarter. Finally, Osaic Holdings Inc. increased its stake in Teleflex by 17.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,247 shares of the medical technology company’s stock valued at $148,000 after purchasing an additional 186 shares in the last quarter. Institutional investors own 95.62% of the company’s stock.

Analyst Upgrades and Downgrades

TFX has been the topic of several research reports. Mizuho lifted their price objective on shares of Teleflex from $130.00 to $135.00 and gave the stock a “neutral” rating in a research report on Friday, August 1st. Wells Fargo & Company lowered their price target on shares of Teleflex from $137.00 to $131.00 and set an “equal weight” rating on the stock in a research report on Friday, August 1st. Royal Bank Of Canada boosted their price target on shares of Teleflex from $130.00 to $135.00 and gave the company a “sector perform” rating in a research report on Friday, August 1st. Weiss Ratings reissued a “sell (d+)” rating on shares of Teleflex in a research report on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Teleflex from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 15th. One investment analyst has rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $141.57.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.